Format

Send to

Choose Destination
Gut. 2016 Aug;65(8):1314-21. doi: 10.1136/gutjnl-2015-311098. Epub 2016 May 24.

Refinement of screening for familial pancreatic cancer.

Author information

1
Department of Visceral, Thoracic and Vascular Surgery, Philipps University Marburg, Marburg, Germany.
2
Department of Medical Oncology, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain.
3
Department of Gastroenterology & Hepatology, Leiden University Medical Center, Leiden, The Netherlands.
4
Department of Radiology, Philipps University Marburg, Marburg, Germany.
5
Department of Gastroenterology and Endocrinology, Philipps University Marburg, Marburg, Germany.
6
Department of Pathology, Philipps University Marburg, Marburg, Germany.
7
Department of Gastroenterology, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain.
8
Department of Radiology, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain.
9
Department of Pathology, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain.
10
Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
11
Department of Radiology, Leiden University Medical Centre, Leiden, The Netherlands.
12
Department of Pathology, Consultation Centre for Pancreatic Tumors, Technical University Munich, Munich, Germany.
13
Department of Visceral, Thoracic and Vascular Surgery, Philipps University Marburg, Marburg, Germany Department of General Surgery, Klinikum Hanau GmbH, Hanau, Germany.

Abstract

OBJECTIVE:

Surveillance programmes are recommended for individuals at risk (IAR) of familial pancreatic cancer (FPC) to detect early pancreatic cancer (pancreatic ductal adenocarcinoma, PDAC). However, the age to begin screening and the optimal screening protocol remain to be determined.

METHODS:

IAR from non-CDKN2A FPC families underwent annual screening by MRI with endoscopic ultrasonography (EUS) in board-approved prospective screening programmes at three tertiary referral centres. The diagnostic yield according to age and different screening protocols was analysed.

RESULTS:

253 IAR with a median age of 48 (25-81) years underwent screening with a median of 3 (1-11) screening visits during a median follow-up of 28 (1-152) months. 134 (53%) IAR revealed pancreatic lesions on imaging, mostly cystic (94%), on baseline or follow-up screening. Lesions were significantly more often identified in IAR above the age of 45 years (p<0.0001). In 21 IAR who underwent surgery, no significant lesions (PDAC, pancreatic intraepithelial neoplasia (PanIN) 3 lesions, high-grade intraductal papillary mucinous neoplasia (IPMN)) were detected before the age of 50 years. Potentially relevant lesions (multifocal PanIN2 lesions, low/moderate-grade branch-duct IPMNs) occurred also significantly more often after the age of 50 years (13 vs 2, p<0.0004). The diagnostic yield of potentially relevant lesions was not different between screening protocols using annual MRI with EUS (n=98) or annual MRI with EUS every 3rd year (n=198) and between IAR screened at intervals of 12 months (n=180) or IAR that decided to be screened at ≥24 months intervals (n=30).

CONCLUSIONS:

It appears safe to start screening for PDAC in IAR of non-CDKN2a FPC families at the age of 50 years. MRI-based screening supplemented by EUS at baseline and every 3rd year or when changes in MRI occur appears to be efficient.

KEYWORDS:

FAMILY CANCER; PANCREATIC CANCER; SCREENING

PMID:
27222532
DOI:
10.1136/gutjnl-2015-311098
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center